Sanctura Co-Promotion Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva
You may also be interested in...
Indevus Sanctura XR To Begin Phase III Trials “Shortly”
Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.
Indevus Sanctura XR To Begin Phase III Trials “Shortly”
Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.
Indevus To Market Nebido In The U.S. Upon Approval
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.